newsfilter
← Latest News
GlobeNewswire·

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and